By Fineline Cube 
Vibrant Therapeutics, an innovative biotech company specializing in next-generation intelligent macromolecule drugs, announced on August 25, 2025, the completion of its multi-million-dollar Series A funding rounds. The Series A+ round was led by Apricot Capital, while the Series A round was led by Trinity-fund with participation from existing investors, including Sequoia China. The funds will primarily be used to advance the company’s core pipeline into global clinical trials and accelerate the development of First-in-Class (FIC) and Best-in-Class (BIC) drugs.
Company Background and Leadership
Founded in 2019 by Dr. Wang Luquan, a co-founder of GenScript, Vibrant Therapeutics’ core leadership team has over 20 years of experience in macromolecule drug R&D on average. Team members have held key positions at renowned pharmaceutical and biotech companies such as Schering-Plough, Merck, and GenScript.
Proprietary Platform and Future Plans
Vibrant Therapeutics’ intelligent molecular design platform employs a “wet-dry combination” R&D model, integrating computational prediction with experimental validation. This efficient, closed-loop process accelerates drug candidate screening and optimization, addressing unmet clinical needs. The funding will also support talent team expansion and the advancement of proprietary projects.-Fineline Info & Tech